“Advancing Precision Therapies for Neurodegeneration”
YepBio is committed to transforming neurodegenerative care through biomarker-guided patient stratification and disease-modifying therapies. Together with partners, investors, and collaborators, we aim to bring first-in-class innovation to patients worldwide.
Challenging Parkinson's with Precision Science
YepBio develops Disease-Modifying Therapeutics targeting PARIS(ZNF746), a genetically validated mitochondrial pathway in Parkinson's disease. Through biomarker-based precision medicine, we aim to fundamentally halt disease progression.
Vision & Roadmap
PARIS-PD precision medicine-based DMT development roadmap
Patient subtype classification · Drug efficacy/tracking
Multi-marker diagnostic kit development
YPD-01 Korea Phase 1 IND approval · Global US-FDA IND filing
CDx core tech establishment · 18 novel biomarker validations
YPD-01 Korea Phase 2 prep · Global US-FDA Phase 1 IND · Indication expansion
CDx clinical patient screening · PDy core tech · Early diagnostic dev/validation
YPD-01 Korea Phase 2 · Global US-FDA Phase 1 complete · Indication expansion
CDx & PDy Phase 2 utilization · Productization · YPD-ASK commercialization (Rapid Kit)
Global L/O · IPO
Building on world-class targeted therapeutics for neurodegenerative diseases, we aim to achieve global licensing-out and IPO success.